This product is a HSP70 expressing oncolytic herpes simplex virus, which is based on HSV-1 with ICP0 deleted. The deletion of ICP0 were attenuated for viral growth, and impaired for viral reactivation when equivalent latent infections were established in vivo. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 1
Backbone
HSV-1 (ΔΔICP0)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Gene Modification
ΔΔICP0
Promoter
CMV
Transgene
HSP70
Type of Transgene
Cytokine
Related Target/Protein
Heat shock protein 70
Capsid Modification
None
Titer
>1*10^8 PFU
Related Diseases
Osteosarcoma
Transgene
Alternative Names
HSP70, APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70, hsp70RY, heat shock protein family A (Hsp70) member 4
The 70 kilodalton heat shock proteins (Hsp70s or DnaK) are a family of conserved ubiquitously expressed heat shock proteins. Proteins with similar structure exist in virtually all living organisms. The Hsp70s are an important part of the cell's machinery for protein folding, and help to protect cells from stress.
Customer Reviews and Q&As
There are currently no customer reviews or questions for HSP70-expressing Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-HSP70 (CyOV-0046XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.